Solid growth masks margin pressure; long-term drivers intact

₹309.1 Cr reported, 25.1% YoY growth from ₹247.1 Cr in Q2 FY'26

H1 FY'27 ₹566.6 Cr vs H1 FY'26 ₹451.1 Cr = 25.6% growth

API ₹250.1 Cr with 30% growth stated; domestic API grew 42%, export grew 8%

Q2 FY'27 gross margin 76.2% vs prior periods ~79.1%, indicating 290 bps contraction in Q2; management attributes to commodity prices and supply chain

Q2 EBITDA ₹104.4 Cr = 33.75%; HY FY'27 33.0% vs HY FY'26 33.2%, flat

₹69.6 Cr = 22.5% of revenue; 10.3% YoY growth from ₹63.1 Cr Q2 FY'26

Formulation ₹58.9 Cr with 6% growth stated; management notes weak growth due to shift from API to formulation procurement

H1 FY'27 grew 26% YoY, supporting forward guidance; Q2 25.1% meets >25% prior guidance minimum

Prior: 40% by FY28. Now: 38%-40% range 'over next few years' post-ramp. Timeline pushed out due to Stelton & injectables low utilization (5% for injectables currently).

FY'24 formulation was ~₹200 Cr; now similar run rate in FY'27. Growth only 6% in Q2 vs company average 25%; procurement shift to APIs cited.

API 30% YoY growth; domestic 42% YoY with new customer wins. Immunosuppressant and oncology double-digit/near-double-digit growth; anti-infectives, antifungal ramping.

₹5,000 Cr India-based market TAM; target ₹400-500 Cr revenue over 4-5 years; fully integrated from API to finished, differentiation via pricing & quality.

TAM ₹5,000 Cr; expected ₹300 Cr top-line over 3-4 years. Currently 5% utilization, customer audits ongoing; material ramp expected H2 FY27.

Anti-infectives, antifungal, oncology grew significantly over last 6 months. Nystattin, Fusidic acid, Mupirocin launching in emerging markets, expanding to global. New U.S. customers qualified, validation supplies underway. Over 2-3 years, expect mid-teens growth assuming historical growth higher; ~30 products in pipeline, 10-15 advanced stages.

Unit-II 21% utilized, injectables (Unit-IV) 5%. Expect ramp via domestic market growth and above-company-average growth from injectables manufacturing. New ANDA approvals (Tofacitinib, Mofetil oral suspension) will drive facility utilization over years.

Expected range 24-25%.

Pricing is to customer; have gained customers via price discounts due to scale & fermentation expertise, offering significant discount vs competitors. No pricing pressure seen. Raw material cost increases prefer to address via R&D and productivity improvements, not customer pass-through (short-term issues).

Concord product range India market ~₹5,000 Cr; fully integrated from API to finished. Dermatology segments: eczema, Tacrolimus, Pimecrolimus, anti-infectives, Fusidic acid, Nystattin, Mupirocin, acne. Strategy: inroads in emerging markets, expand geographies within India; 4-5 years to scale from ₹100 Cr to ₹400-500 Cr; fully integrated, significant market share confidence.

Steps: renewable energy investment (positive impact), invest in Stelton & injectables (growth drivers). Without these, normalized margin ~38%. Over next few years expect 38%-40% range (historical EBITDA levels) once these units contribute materially. Also Unit-III Limbasi ramp.

₹20-30 Cr maintenance per year; ₹50-60 Cr total each year; in the tune of ₹100-120 Cr.

TAM ~₹5,000 Cr; close to ₹300 Cr top-line potential over 3-4 years from domestic/export markets. Discussing with large customers; built ~₹300 Cr top-line capacity over next 3-4 years. Multiple product injectables discussion ongoing; customers taking first step (audits). Few contracts expected to materialize in H2.

API to formulation mix ~78-22 ratio historically; expected 80-20 split. API formulation business pretty similar lines, 80-20. Significant contributor to margin compression is raw material pricing (solvents, power, fuel costs, geopolitical disruptions). Injectables at 5% utilization, hasn't impacted gross margins materially yet.

₹2M/year from one commercial project (annual perspective). CDMO not classified for third-party contract manufacturing (IPR with third party). Only one commercial project; exploring with couple more. Opportunity size being built; customer launching almost a year and a half back, now building on U.S. platform.

Growth FY'27 expected slightly better than historical 18%. H1 26%, fair visibility on Q3. Over 3-5 year period grown 18-19%; this year also better. Last year's degrowth was global phenomenon (not structural). Q2 visibility and Q3 numbers show momentum. Expected to grow slightly better than 18% for FY'27.

New products launched 3-4 years back now commercialized; Nystattin, Fusidic acid growing significantly. 30+ products in pipeline; 10-15 in advanced stages. Products will grow faster than mature products but from smaller base; will take time to reach mature product levels. Concord well-positioned on niche fermentation APIs; competition from Europe/Southeast Asia; good position to gain share on new products.

Immunosuppressant growing in line with company growth rate and historically. Six months growth in line with company growth; gaining market share (customer wallet share expansion). Latin America opening up post-ANVISA inspections (second source conversions). Discussions advanced with customers on immunosuppressant APIs; ANVISA inspections playing out (inspect/audit → approval → 4-5 months); expect second source conversions, Latin America growth.

Stelton materials supplied H1, traction starting now in U.S. for formulations. H2 expected meaningful contributions; once Stelton ramping sale, positive contributions help move 33-34% slightly towards numbers. INCA division continuing engagement with doctors; cost structures given (Stelton, injectables expenses); once Stelton starts ramping, expect move from 33-34% to 38-39%, one reason why report lower baseline understanding the gap and efforts.

Unit-I 75%, Unit-II 55%, Unit-III (new) on ramp, Unit-IV (injectables) 5%.

H1 FY'27 achieved 26% YoY; Q3 visibility on existing contracts and customer additions; target comfortably above 18% baseline

Historically 18-19% API growth; 30+ products in pipeline, 10-15 advanced stages; new geographies (U.S., Latin America, Japan) opening; execution risk on ramp rates

Quantified target from prior call; incremental drivers include injectables (₹300 Cr potential), Inspira (₹400-500 Cr potential), Stelton (ramp phase); timeline ambitious

Prior guidance: 40% by FY28 (now shifted to 'over next few years'). Timeline extended due to Stelton & injectables low utilization ramp. Normalized margin excluding new units ~37.8%

Currently impacted by raw material inflation (solvents, power, fuel). Management expects recovery post-renewable energy payback and cost normalization; near-term headwind remains

Disciplined allocation; maintenance CapEx steady; growth CapEx for new facilities (injectables, Stelton) and capacity expansion

Q2 gross margin 76.2% vs 79.1% prior = 290 bps contraction. Raw material costs (solvents), power, fuel inflation cited as temporary. No clear timeline for recovery; margin compression may persist if commodity pressures extend into FY'28.

Injectables facility at 5% utilization (Unit-IV); Stelton (U.S. formulation) nascent; both critical to EBITDA margin expansion (38%-40% target). Customer audits for injectables ongoing; contracts expected H2 but timing uncertain. Depreciation drag and startup costs reduce margins short-term.

Formulation revenue ₹58.9 Cr grew only 6% in Q2 vs company average 25%. Historical FY'24 formulation baseline ~₹200 Cr, now flat; indicates business maturity or market saturation. Customer procurement shift from formulations to APIs for emerging market operations limits upside.

Injectable facility TAM ₹5,000 Cr; expected ₹300 Cr top-line over 3-4 years from 'large domestic and global customers.' Details withheld; suggests significant customer concentration. Loss of one major customer could materially impact injectable business ramp.

Raw material costs (solvents) cited as primary margin compression driver. Geopolitical uncertainties and broader supply chain disruptions mentioned. No alternative sourcing or hedging strategy disclosed. Solvents are fermentation-critical input.

CDMO revenue ₹2M/year from one commercial project; nascent stage. Management deflected guidance, saying 'not a true reflection of work being done.' Suggests project is developmental rather than revenue-generating. Risk of long commercialization timeline or project failure.